Changeflow GovPing Healthcare & Life Sciences Cancer Treatment Pharmaceutical Combination Pat...
Routine Rule Added Final

Cancer Treatment Pharmaceutical Combination Patent - Johannes Gutenberg-Universität Mainz

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published application EP3790582A1 for a pharmaceutical combination for use in cancer treatment, filed by Universitätsmedizin der Johannes Gutenberg-Universität Mainz. Inventors include Rosigkeit, Bockamp, and Schuppan, with IPC classifications covering therapeutic antibodies (C07K 16/28), immunomodulators (A61K 39/395, A61K 39/39), and antisense compounds (C12N 15/117). The patent application was published on April 15, 2026.

“A PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF CANCER”

EPO , verbatim from source
Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 34 changes logged to date.

What changed

The EPO published European patent application EP3790582A1 for a pharmaceutical combination directed to cancer treatment (A61P 35/00). The application claims combinations including therapeutic antibodies, immunological adjuvants, and antisense nucleic acids.

For parties in the pharmaceutical and biotechnology sectors, this patent grant establishes intellectual property rights in the designated contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). Freedom-to-operate analyses for cancer therapies in these territories should account for this publication.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

A PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF CANCER

Publication EP3790582A1 Kind: A1 Apr 15, 2026

Applicants

Universitätsmedizin der
Johannes Gutenberg-Universität Mainz

Inventors

ROSIGKEIT, Sebastian, BOCKAMP, Ernst-Otto, SCHUPPAN, Detlev

IPC Classifications

A61K 39/395 20060101AFI20191115BHEP A61K 39/39 20060101ALI20191115BHEP C07K 16/28 20060101ALI20191115BHEP C12N 15/117 20100101ALI20191115BHEP A61P 35/00 20060101ALI20191115BHEP A61K 39/00 20060101ALI20191115BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Medical device makers Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing IP licensing Research and development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!